CD8A and neoplasm: Intraperitoneal injection of ADU-S100 into mouse models with peritoneal carcinomatosis of ovarian cancer (ID8) and MC38 colon carcinoma observed inhibition of peritoneal carcinomatosis and malignant ascites progression.ADU-100 effectively reduced abnormal tumor vasculature formation by activating STING-mediated type I IFN and upregulated the number of CD8+ T cells, enhancing the remaining tumor vasculature of pericyte coverage, thereby inhibiting the formation of malignant ascites in the peritoneal cavity.